Continuation Treatment Protocol for Patients Who Participated in the Adagio TVP 1012/501 Clinical Trial

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2012 by Rabin Medical Center.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by (Responsible Party):
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT01709461
First received: October 14, 2012
Last updated: October 16, 2012
Last verified: June 2012
  Purpose

the purpose of the study is to extend the use of Rasagelin Mesylate 1mg per day by subjects who participated in the Adagio TVP 1012/501 according to form 4a for additional three years.


Condition
Parkinson Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Continue Providing Care for Patient Who Participated in the Adagio TVP 1012/501 Clinical Trial

Resource links provided by NLM:


Further study details as provided by Rabin Medical Center:

Estimated Enrollment: 12
Study Start Date: October 2012
  Eligibility

Ages Eligible for Study:   30 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

subjects who took part in the TVP 1012/501 clinical trial and willing to contiue receiving Rasgiline Mesylate.

Criteria

Inclusion Criteria:

  • subjects who are willing to contiue this treatment.
  • subjects who took part in the TVP 1012/501 clinical trail.

Exclusion Criteria:

  • subjects who didn't take part in the TVP 1012/501 clinical trail.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01709461

Contacts
Contact: Ruth Djaldetti, Professor 972-9378218/9 ruthdjal@clalit.org.il
Contact: Yaniv roditi, Msc 972-39236843 yar@clalit.org.il

Locations
Israel
Rabin Medical Center Beilinson Campus Not yet recruiting
Petach Tiqva, Hamerkaz, Israel, 49100
Principal Investigator: Ruth Djaldetti, Professor         
Sponsors and Collaborators
Rabin Medical Center
  More Information

No publications provided

Responsible Party: Rabin Medical Center
ClinicalTrials.gov Identifier: NCT01709461     History of Changes
Other Study ID Numbers: RD 06 - 12
Study First Received: October 14, 2012
Last Updated: October 16, 2012
Health Authority: Israeli: Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders

ClinicalTrials.gov processed this record on October 23, 2014